Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07DWF
|
|||
| Former ID |
DNCL002298
|
|||
| Drug Name |
ARQ 092
|
|||
| Synonyms |
Miransertib
Click to Show/Hide
|
|||
| Indication | Proteus syndrome [ICD-11: LD2C; ICD-10: Q87.3] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Company |
ArQule; Daiichi
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H24N6
|
|||
| Canonical SMILES |
C1CC(C1)(C2=CC=C(C=C2)N3C4=C(C=CC(=N4)C5=CC=CC=C5)N=C3C6=C(N=CC=C6)N)N
|
|||
| InChI |
1S/C27H24N6/c28-24-21(8-4-17-30-24)25-32-23-14-13-22(18-6-2-1-3-7-18)31-26(23)33(25)20-11-9-19(10-12-20)27(29)15-5-16-27/h1-4,6-14,17H,5,15-16,29H2,(H2,28,30)
|
|||
| InChIKey |
HNFMVVHMKGFCMB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1313881-70-7
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04316546) ARQ 092 (Miransertib) in Proteus Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01473095) Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.